Peanut Allergy Treatment Industry Report 2025-2034: Market Dynamics, Trends, And Forecasts

The Peanut Allergy Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Expected Peanut Allergy Treatment Market Size During the Forecast Period?
The peanut allergy treatment market, valued at $0.45 billion in 2024, is projected to increase to $0.51 billion in 2025, growing at a CAGR of 11.4%. The growth is attributed to the increasing prevalence of peanut allergies, advancements in diagnostic testing, greater public awareness and concern, the development of early intervention strategies, and regulatory approvals for treatments.

The peanut allergy treatment market is anticipated to grow to $0.77 billion by 2029, with a CAGR of 11.1%. This growth is attributed to the continued rise in prevalence, the development of personalized medicine, new immunotherapy treatments, increased investments, and the expansion of telemedicine. Major trends include the adoption of immunotherapy, advancements in biologic therapies, the use of probiotic-based treatments, innovations in delivery systems, personalized medicine approaches, and regulatory support.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15888

What Are the High-Growth Segments in the Peanut Allergy Treatment Market?
The peanut allergy treatment market covered in this report is segmented -

1) By Drug Class: Antihistamines, Immunotherapies, Epinephrine, Other Drug Classes
2) By Route Of Administration: Injectable, Oral, Other Routes Of Administration
3) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Other Distribution Channels

Subsegments:
1) By Antihistamines: Oral Antihistamines, Topical Antihistamines
2) By Immunotherapies: Oral Immunotherapy (OIT), Sublingual Immunotherapy (SLIT), Epicutaneous Immunotherapy (EPIT)
3) By Epinephrine: Epinephrine Auto-Injectors, Epinephrine Inhalers
4) By Other Drug Classes: Leukotriene Receptor Antagonists, Monoclonal Antibodies, Corticosteroids

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15888&type=smp

What Key Drivers Are Expected to Influence Future Peanut Allergy Treatment Market Growth?
Increased investment in research and development for allergy treatments is expected to drive the growth of the peanut allergy treatment market. R&D funding is essential for the advancement of therapies for peanut allergies, including innovative immunotherapies and desensitization techniques. For example, in January 2024, the Victorian Government announced a $12 million investment in Aravax, an Australian biotech company, to support its development of PVX108, a promising immunotherapy for peanut allergies. This investment is expected to have a global impact on public health, advancing peanut allergy treatments.

Which Companies Hold the Largest Share Across Different Peanut Allergy Treatment Market Segments?
Major companies operating in the peanut allergy treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Limited, Viatris Inc., Regeneron Pharmaceuticals Inc., Hikma Pharmaceuticals plc, ALK-Abelló A/S, Amneal Pharmaceuticals Inc., Amphastar Pharmaceuticals Inc., Stallergenes Greer plc, kaleo Inc., Aquestive Therapeutics Inc., Vedanta Biosciences Inc., Aimmune Therapeutics Inc., AnaptysBio Inc., Alladapt Immunotherapeutics Inc., Aravax Pty Ltd., Intrommune Therapeutics Inc., IgGenix Inc., DBV Technologies SA, Camallergy Ltd., HAL Allergy Group, Prota Therapeutics Pty Ltd.

What Trends Are Expected to Dominate the Peanut Allergy Treatment Market in the Next 5 Years?
Companies in the peanut allergy treatment market are advancing biologic treatments, such as anti-IgE monoclonal antibodies, to deliver more targeted peanut allergy therapies and improve patient health outcomes. These antibodies neutralize IgE, which is responsible for allergic reactions. For instance, in February 2024, Switzerland-based Novartis Pharmaceuticals Corporation received FDA approval for Xolair (omalizumab) to reduce allergic responses, including anaphylaxis, in patients aged one year and older. The approval was supported by results from the NIH-sponsored Phase III OUtMATCH study, which demonstrated increased food allergy tolerance in patients using Xolair compared to a placebo.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/peanut-allergy-treatment-global-market-report

What Are the Emerging Geographies for The Peanut Allergy Treatment Market Growth?
North America was the largest region in the peanut allergy treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peanut allergy treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Peanut Allergy Treatment Market?
2. What is the CAGR expected in the Peanut Allergy Treatment Market?
3. What Are the Key Innovations Transforming the Peanut Allergy Treatment Industry?
4. Which Region Is Leading the Peanut Allergy Treatment Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.